Lyell Immunopharma, Inc. (LYEL) fundamentals score
Lyell Immunopharma is a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Its goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.6 out of 10, Weak long-term fundamentals
- Growth: 4.3/10
- Profitability: 1.0/10
- Financial health: 5.2/10
- Earnings quality: 7.0/10
- Valuation: 1.5/10
Scores are calculated from Lyell Immunopharma, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10